Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Revolution Medicines executive sells over $619k in company stock

Published 13/04/2024, 01:12

Mark A. Goldsmith, a key executive at Revolution Medicines, Inc. (NASDAQ:RVMD), has recently sold a significant amount of company stock, as reported in the latest SEC filings. The transactions, which took place on April 10, 2024, involved the sale of 17,500 shares of common stock, resulting in a total of over $619,467.

The sales were executed in multiple transactions at prices ranging from $35.3317 to $35.4829. This range reflects the weighted average sale prices, with the specific number of shares sold at each price available upon request to the appropriate parties, as per the SEC filing notes.

Goldsmith's role at Revolution Medicines is indicated as "See Remarks" in the SEC filing, which further clarifies in the remarks section that he serves as the President and Chief Executive Officer of the company. The shares sold were held both directly by Goldsmith and indirectly through trusts. Footnotes in the SEC document specify that some of the shares are held by trusts for the benefit of Goldsmith's family members, while others are part of the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

The SEC form also notes that these transactions were made pursuant to a Rule 10b5-1 trading plan, which was adopted by Goldsmith on December 1, 2023. Such plans allow company insiders to sell shares over a predetermined schedule to avoid concerns about transactions based on nonpublic information.

Following the sale, Goldsmith still holds a substantial number of shares in the company, including 232,000 restricted stock units, as indicated by the footnotes. The remaining shares reflect his continued investment in the company's future.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

Investors and market watchers often pay close attention to insider trading patterns for clues about a company's prospects. Transactions like these are publicly reported to ensure transparency and maintain fair trading practices in the markets.

InvestingPro Insights

As market participants digest the news of Mark A. Goldsmith's recent stock sale, a closer look at Revolution Medicines, Inc. (NASDAQ:RVMD) through InvestingPro reveals a nuanced financial landscape. According to real-time data, Revolution Medicines has a market capitalization of roughly $5.94 billion, indicating its significant presence in the biotech industry despite its challenges.

InvestingPro data highlights that the company's P/E ratio stands at -9.23, reflecting investor sentiment about its earnings potential. This is further underscored by an adjusted P/E ratio for the last twelve months as of Q4 2023, which sits at -12.68. The negative values point to the lack of profitability during this period, aligning with one of the InvestingPro Tips that analysts do not anticipate the company will be profitable this year. Moreover, the company's revenue has faced a sharp decline, with a -67.27% change over the last twelve months as of Q4 2023.

Two InvestingPro Tips that could be particularly insightful for investors in light of the recent insider trading activity are:

  1. Revolution Medicines holds more cash than debt on its balance sheet, which could provide some financial stability and flexibility.
  2. The company's stock price movements are quite volatile, which may need to be considered when interpreting insider transactions like those of Goldsmith.

For those considering a deeper analysis, InvestingPro offers a total of 9 additional tips for Revolution Medicines, available at their specific company page. Investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which can provide further insights into the company's financial health and future prospects.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.